CHRNA7 and neoplasm: Based on the impact that the knockout of CHRNA7 had on tumor progression and survival, as well as changes in myeloid immune cell gene expression and tumor infiltration, we chose to perform in vivo testing of AR-R17779 on breast tumor–bearing immune-competent mice.